EXT608 not checked

Extend Biosciences Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Modified version of parathyroid hormone attached to vitamin D to extend half-life”In the company’s words, NCT06988670 on ClinicalTrials.gov
Tested for
Hypoparathyroidism
Main trialPhase 2
“The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.”In the company’s words, NCT06988670 on ClinicalTrials.gov
Other names
test drug

Other drugs for Hypoparathyroidism

All 6 drugs for Hypoparathyroidism

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting May 2027 A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
Phase 1Completed 13 Jun 2023 A Phase 1 Study of EXT608 in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow EXT608

Following is part of Solo: you see every change to EXT608 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in